Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

BACKGROUND: Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients re...

Descripción completa

Detalles Bibliográficos
Autores principales: Biran, Noa, Ip, Andrew, Ahn, Jaeil, Go, Ronaldo C, Wang, Shuqi, Mathura, Shivam, Sinclaire, Brittany A, Bednarz, Urszula, Marafelias, Michael, Hansen, Eric, Siegel, David S, Goy, Andre H, Pecora, Andrew L, Sawczuk, Ihor S, Koniaris, Lauren S, Simwenyi, Micky, Varga, Daniel W, Tank, Lisa K, Stein, Aaron A, Allusson, Valerie, Lin, George S, Oser, William F, Tuma, Roman A, Reichman, Joseph, Brusco, Louis, Carpenter, Kim L, Costanzo, Eric J, Vivona, Vincent, Goldberg, Stuart L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428303/
https://www.ncbi.nlm.nih.gov/pubmed/32838323
http://dx.doi.org/10.1016/S2665-9913(20)30277-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428303/
https://www.ncbi.nlm.nih.gov/pubmed/32838323
http://dx.doi.org/10.1016/S2665-9913(20)30277-0

Ejemplares similares